Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Seattle Genetics Inc. (Nasdaq: SGEN)

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company's lead program, ADCETRIS (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Celldex, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. *

 

Period Start 1997-01-01 established
Product Industry BIOTECH
     
Region Region Bothell, WA
  Country United States (USA)
  Street 21717 30th Drive S.E.
  City 98021 Bothell, WA
  Tel +1-425-527-4000
    Address record changed: 2013-06-30
     
Basic data Employees n. a.
  Currency USD
  Annual sales 22,420,000 (revenue, consolidated (2007) 2007-12-31)
  Profit -48,932,000 (2007-12-31)
  Cash 111,361,000 (2007-12-31)
     
    * Document for �About Section�: Seattle Genetics, Inc.. (6/25/13). "Press Release: Seattle Genetics Enters into New Antibody-Drug Conjugate Collaboration with Bayer". Bothell, WA.
     
   
Record changed: 2019-08-29

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Seattle Genetics Inc. (Nasdaq: SGEN)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top